article thumbnail

Negative Customer Acquisition Costs - Creative Startup Marketing Ideas - Eric David Greenspan

SoCal CTO

Sometimes I make a blog entry. Some days I respond to questions asked by folks like yourself, the press, or an entity doing a case study, i.e. Citrix, RIM, USC. Our new customer acquisition has grown and our costs have plummeted. A negative customer acquisition cost! Just found the title of my post.

article thumbnail

What Does the Post Crash VC Market Look Like?

Both Sides of the Table

What You Can Learn From Public Markets It doesn’t really take a genius to realize that what happens in the public markets will filter back to the private markets because the ultimate exit of these companies is either an IPO or an acquisition (often by a public company whose valuation is fixed daily by the market). It’s just math.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Bio Roundup: IDO Fallout, Express Scripts Dumps Amgen, Isaly Out & More

Xconomy

Here’s a case study of how fast things can change in biopharma. Through acquisitions and alliances, they rolled out a spate of large-scale combination trials. For a few years, a type of cancer drug called an IDO inhibitor was all the rage, a promising path to expanding the reach of immunotherapy. Major drug makers were dealing, too.

article thumbnail

Why The Haters are Wrong About Growth Hacking

Both Sides of the Table

We go through case studies like how Mint.com & Magento drove large audiences through great content marketing strategies. I tell people that they need to blog about their industry to drive customers and not blog to their egos to drive their peer group to their blogs.

article thumbnail

This Week in Venture Capital – Episode 3

Both Sides of the Table

Finally, a lot of people asking me about typos on my blog. Studying for the SAT, LSAT, GMAT, TOEFL, MCAT and other standardized tests in the US is a massive market that has been dominated for years by Kaplan and Princeton Review. Blogging has gone through many iterations. I use Wordpress for this blog and it’s great.

article thumbnail

Takeda Bases PvP Biologics Buyout on Promising Early Celiac Drug Data

Xconomy

The deal follows completion of a Phase 1 study evaluating the PvP drug. Takeda (NYSE: TAK ) acquired the company for an undisclosed amount up front, plus up to $330 million in payments based on development and regulatory milestones for PvP’s experimental celiac disease drug KUMA062 (now TAK-062).

article thumbnail

Phoenix Shops Its Cancer Drug as Potential Alzheimer’s Treatment

Xconomy

Over more than two decades, Perry has studied the possibility that diseases like Alzheimer’s may get their start because the body produces too many variants of oxygen, called free radicals, which cause cell damage, and not enough antioxidants to limit the damage.

Study 68